Literature DB >> 8994317

Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study.

O E Girgsdies1, G Rosenkranz.   

Abstract

A total of 522 children between 18 months and 14 years and 191 adults between 18 and 60 years were vaccinated with TBE-vaccine according to an abbreviated schedule (0, 7, 21). The aim of the study was to investigate whether reducing the amount of antigen in the vaccination for children would preserve an adequate immune response and decrease the rate of side-effects. Efficacy was determined on the extent to which children, vaccinated with the low doses (0.4 microgram or 0.75 microgram), reacted by developing antibodies in the same way as adults treated with the approved dose of 1.5 micrograms (equivalence of titres). The titres obtained in the children with the two lower doses were equivalent to those in the adults obtained with the standard dose. Titres decreased in the children with increasing age. Children older than 12 years in the approved dosage group had the same median titres as adults. The frequency of side-effects in the two lower dose groups, especially raised temperature, was markedly reduced. Whereas 30.1% of the children vaccinated with the approved dose had raised temperature higher than 38 degrees C only 18.8% and 18.4%, respectively, of the children vaccinated with the lower doses developed such temperatures. This improved tolerance in terms of raised temperature was also reflected in the other general reactions such as tiredness, joint pain or headache.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8994317     DOI: 10.1016/s0264-410x(96)00081-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Tick-borne Encephalitis Vaccines.

Authors:  Axel T Lehrer; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011

2.  Cost-benefit analysis of vaccination against tick-borne encephalitis among French troops.

Authors:  Guillaume Desjeux; Laurent Galoisy-Guibal; Cyrille Colin
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  [FSME monitoring: monitoring of adverse events of tick-borne-encephalitis vaccines by selected paediatricians and general practitioners].

Authors:  Robert Weinzettel; Susanne Ertl; Karl Zwiauer
Journal:  Wien Med Wochenschr       Date:  2007

Review 4.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Vaccines for preventing tick-borne encephalitis.

Authors:  Vittorio Demicheli; Maria Grazia Debalini; Alessandro Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

6.  Adverse reactions to tick-borne encephalitis vaccine: FSME-Immun.

Authors:  A Grzeszczuk; E Sokolewicz-Bobrowska; D Prokopowicz
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 7.455

Review 7.  Historical Perspectives on Flavivirus Research.

Authors:  Michael R Holbrook
Journal:  Viruses       Date:  2017-04-30       Impact factor: 5.048

8.  Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus.

Authors:  Marilena P Etna; Aurora Signorazzi; Daniela Ricci; Martina Severa; Fabiana Rizzo; Elena Giacomini; Andrea Gaggioli; Isabelle Bekeredjian-Ding; Anke Huckriede; Eliana M Coccia
Journal:  PLoS Pathog       Date:  2021-04-15       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.